FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2156671134> ?p ?o ?g. }

• W2156671134 endingPage "1500" @default.
• W2156671134 startingPage "1500" @default.
• W2156671134 abstract "Back to table of contents Previous article Next article LetterFull AccessDivalproex-Induced Alopecia: A Case ReportTehmina A. Khan, M.D., Huaibao Sheng, M.D., Yekaterina K. Mercke, M.D., and Steven B. Lippmann, M.D.Tehmina A. KhanSearch for more papers by this author, M.D., Huaibao ShengSearch for more papers by this author, M.D., Yekaterina K. MerckeSearch for more papers by this author, M.D., and Steven B. LippmannSearch for more papers by this author, M.D.Published Online:1 Nov 1999https://doi.org/10.1176/ps.50.11.1500AboutSectionsView EPUB ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinked InEmail To the Editor: Hair loss may occur as a side effect of pharmacotherapy with mood stabilizers. Valproic acid and divalproex (a combination of valproic acid and valproate) dissociate to valproate in vivo and are well-established causes of alopecia (1,2,3). This case report describes a patient who developed acute transient alopecia of all scalp hair after ingesting a large overdose of divalproex.The patient, a 30-year-old white woman, was hospitalized in a comatose condition after ingesting from 25,000 to 40,000 mg of divalproex in a suicide attempt (from 100 to 150 tablets, 250 mg each). She had been under treatment for bipolar disorder, polysubstance abuse, and posttraumatic epilepsy since 1996 and had been receiving divalproex in oral doses ranging between 1.5 and 3 grams a day.On admission, the patient was experiencing respiratory insufficiency that necessitated intubated mechanical ventilation. Supportive care was provided along with gastric emptying and administration of charcoal and magnesium citrate to reduce drug absorption and shorten bowel emptying time. Her initial serum valproate concentration was 1,100 μg/mL, compared with 83 to 130 μg/mL obtained on her normal oral doses. Results of routine laboratory studies, including a thyroid profile, were unremarkable. The day after admission, her valproate concentration dropped to 700 μg/mL.In the critical care unit, the patient developed aspiration pneumonia and a urinary tract infection, which were treated with ampicillin, ciprofloxacin, piperacillin with tazobactam, vancomycin, trimethoprim-sulfamethoxazole, acetylcystein, guaifenecin, and fluconazole as an antifungal prophylaxis. Atrial fibrillation was managed using adenosine, digoxin, diltiazem, and furosemide. Codeine, meperidine, morphine, acetaminophen, and ibuprofen were given alternatively as analgesics, and haloperidol, lorazepam, and midazolam were prescribed as calmative agents. Famotidine was administered for protection against stress ulcers.While in the hospital, the patient lost all her scalp hair. She was discharged on divalproex, 1.25 grams a day, and remained stable. Her hair growth returned to normal over the next few weeks.Alopecia is a frequent side effect of valproate products (1,2,3). A literature review revealed 643 patients who developed a valproate-associated hair loss (1). Up to 12 percent of patients on the drug suffer from temporary alopecia (2). A prospective study of 78 subjects who were receiving valproate found that hair loss occurred in 6 percent (4).In most cases hair loss is associated with long-term pharmacotherapy and is frequently dose related; up to 28 percent of patients exposed to higher doses can experience alopecia, while lower doses pose less risk (5). We are aware of no reported cases of alopecia in acute overdoses of valproate.The patient described in this report had no hair loss during years of divalproex treatment but exhibited transient, complete alopecia following a massive overdose. Her hair growth returned to normal while she continued to take the medicine. Among all the other drugs administered during the critical care period, only diltiazem, famotidine, fluconazole, haloperidol, and ibuprofen are known to be associated with alopecia, but this side effect is uncommon with these drugs, and the patient's exposure to them was brief. Given the comparatively higher incidence of hair loss with divalproex and the massive degree of toxicity in this case, divalproate is the most likely cause. A cumulative, multifactoral causation is also possible. Further clinical observations may clarify the association between divalproex overdose and alopecia.The authors are associated with the department of psychiatry and behavioral sciences at the University of Louisville School of Medicine in Louisville, Kentucky.References1. Pillans PI, Woods DJ: Drug-associated alopecia. International Journal of Dermatology 14:149-158, 1995Crossref, Google Scholar2. McKinney PA, Finkenbine RD, DeVane CL: Alopecia and mood stabilizer therapy. Annals of Clinical Psychiatry 8:183-185, 1996Crossref, Medline, Google Scholar3. Keck P, McElroy: Antiepileptic drugs, in the American Psychiatric Press Textbook of Psychopharmacology, 2nd ed. Edited by Schatzberg AF, Nemeroff CB. Washington, DC, American Psychiatric Press, 1998Google Scholar4. Calabrese JR, Markovitz PJ, Kimmel SE, et al: Spectrum of efficacy of valproate in 78 rapid-cycling bipolar patients. Journal of Clinical Psychopharmacology 12:53S-56S, 1992Crossref, Medline, Google Scholar5. Beydoun A, Sackellares JC, Shu V: Safety and efficacy of divalproex sodium monotherapy in partial epilepsy: a double-blind, concentration-response design clinical trial. Neurology 48:182-188, 1997Crossref, Medline, Google Scholar FiguresReferencesCited byDetailsCited byPsychosomatics, Vol. 55, No. 1Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology, Vol. 20, No. 3Expert Opinion on Pharmacotherapy, Vol. 9, No. 2 Volume 50Issue 11 November 1999Pages 1500-1500 Metrics History Published online 1 November 1999 Published in print 1 November 1999" @default.
• W2156671134 created "2016-06-24" @default.
• W2156671134 creator A5018430748 @default.
• W2156671134 creator A5036488478 @default.
• W2156671134 creator A5063048952 @default.
• W2156671134 creator A5078333254 @default.
• W2156671134 date "1999-11-01" @default.
• W2156671134 modified "2023-09-27" @default.
• W2156671134 title "Divalproex-Induced Alopecia: A Case Report" @default.
• W2156671134 doi "https://doi.org/10.1176/ps.50.11.1500" @default.
• W2156671134 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10543866" @default.
• W2156671134 hasPublicationYear "1999" @default.
• W2156671134 type Work @default.
• W2156671134 sameAs 2156671134 @default.
• W2156671134 citedByCount "6" @default.
• W2156671134 countsByYear W21566711342014 @default.
• W2156671134 countsByYear W21566711342023 @default.
• W2156671134 crossrefType "journal-article" @default.
• W2156671134 hasAuthorship W2156671134A5018430748 @default.
• W2156671134 hasAuthorship W2156671134A5036488478 @default.
• W2156671134 hasAuthorship W2156671134A5063048952 @default.
• W2156671134 hasAuthorship W2156671134A5078333254 @default.
• W2156671134 hasConcept C118552586 @default.
• W2156671134 hasConcept C16005928 @default.
• W2156671134 hasConcept C187212893 @default.
• W2156671134 hasConcept C2775858608 @default.
• W2156671134 hasConcept C2776174506 @default.
• W2156671134 hasConcept C2776360568 @default.
• W2156671134 hasConcept C2776809841 @default.
• W2156671134 hasConcept C2777172819 @default.
• W2156671134 hasConcept C2778186239 @default.
• W2156671134 hasConcept C2780550438 @default.
• W2156671134 hasConcept C2780733359 @default.
• W2156671134 hasConcept C2908949014 @default.
• W2156671134 hasConcept C71924100 @default.
• W2156671134 hasConceptScore W2156671134C118552586 @default.
• W2156671134 hasConceptScore W2156671134C16005928 @default.
• W2156671134 hasConceptScore W2156671134C187212893 @default.
• W2156671134 hasConceptScore W2156671134C2775858608 @default.
• W2156671134 hasConceptScore W2156671134C2776174506 @default.
• W2156671134 hasConceptScore W2156671134C2776360568 @default.
• W2156671134 hasConceptScore W2156671134C2776809841 @default.
• W2156671134 hasConceptScore W2156671134C2777172819 @default.
• W2156671134 hasConceptScore W2156671134C2778186239 @default.
• W2156671134 hasConceptScore W2156671134C2780550438 @default.
• W2156671134 hasConceptScore W2156671134C2780733359 @default.
• W2156671134 hasConceptScore W2156671134C2908949014 @default.
• W2156671134 hasConceptScore W2156671134C71924100 @default.
• W2156671134 hasIssue "11" @default.
• W2156671134 hasLocation W21566711341 @default.
• W2156671134 hasLocation W21566711342 @default.
• W2156671134 hasOpenAccess W2156671134 @default.
• W2156671134 hasPrimaryLocation W21566711341 @default.
• W2156671134 hasRelatedWork W2010520341 @default.
• W2156671134 hasRelatedWork W2022501784 @default.
• W2156671134 hasRelatedWork W2030567557 @default.
• W2156671134 hasRelatedWork W204919037 @default.
• W2156671134 hasRelatedWork W2092753016 @default.
• W2156671134 hasRelatedWork W2113177593 @default.
• W2156671134 hasRelatedWork W2160950149 @default.
• W2156671134 hasRelatedWork W2467701142 @default.
• W2156671134 hasRelatedWork W4231774701 @default.
• W2156671134 hasRelatedWork W74237609 @default.
• W2156671134 hasVolume "50" @default.
• W2156671134 isParatext "false" @default.
• W2156671134 isRetracted "false" @default.
• W2156671134 magId "2156671134" @default.
• W2156671134 workType "article" @default.